| Literature DB >> 32764347 |
Janaina Macedo-da-Silva1, Claudio Romero Farias Marinho2, Giuseppe Palmisano1, Livia Rosa-Fernandes1,2.
Abstract
Congenital abnormalities cause serious fetal consequences. The term TORCH is used to designate the most common perinatal infections, where: (T) refers to toxoplasmosis, (O) means "others" and includes syphilis, varicella-zoster, parvovirus B19, zika virus (ZIKV), and malaria among others, (R) refers to rubella, (C) relates to cytomegalovirus infection, and (H) to herpes simplex virus infections. Among the main abnormalities identified in neonates exposed to congenital infections are central nervous system (CNS) damage, microcephaly, hearing loss, and ophthalmological impairment, all requiring regular follow-up to monitor its progression. Protein changes such as mutations, post-translational modifications, abundance, structure, and function may indicate a pathological condition before the onset of the first symptoms, allowing early diagnosis and understanding of a particular disease or infection. The term "proteomics" is defined as the science that studies the proteome, which consists of the total protein content of a cell, tissue or organism in a given space and time, including post-translational modifications (PTMs) and interactions between proteins. Currently, quantitative bottom-up proteomic strategies allow rapid and high throughput characterization of complex biological mixtures. Investigating proteome modulation during host-pathogen interaction helps in elucidating the mechanisms of infection and in predicting disease progression. This "molecular battle" between host and pathogen is a key to identify drug targets and diagnostic markers. Here, we conducted a survey on proteomic techniques applied to congenital diseases classified in the terminology "TORCH", including toxoplasmosis, ZIKV, malaria, syphilis, human immunodeficiency virus (HIV), herpes simplex virus (HSV) and human cytomegalovirus (HCVM). We have highlighted proteins and/or protein complexes actively involved in the infection. Most of the proteomic studies reported have been performed in cell line models, and the evaluation of tissues (brain, muscle, and placenta) and biofluids (plasma, serum and urine) in animal models is still underexplored. Moreover, there are a plethora of studies focusing on the pathogen or the host without considering the triad mother-fetus-pathogen as a dynamic and interconnected system.Entities:
Keywords: TORCH; congenital abnormalities; infections; mass spectrometry; pregnancy; proteomics
Mesh:
Year: 2020 PMID: 32764347 PMCID: PMC7464470 DOI: 10.3390/genes11080894
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
Figure 1Most frequent symptoms related to TORCH (toxoplasmosis, “others”, rubella, cytomegalovirus infection, and herpes simplex virus infections) diseases. Children can present these symptoms at birth or late, therefore medical follow-up is crucial (A). Main stages of bottom-up and top-down proteomic analysis. Different tissues, cell culture or fluids can be analyzed (B).
Main symptoms identified in neonates exposed to congenital infections. The + sign means that the indicated symptom has already been related to the disease; while the sign - means that the symptom has little or no relation. Zika virus (ZIKV), human immunodeficiency virus (HIV), human cytomegalovirus (CVM), herpes simplex virus (HSV).
| Disease | Intracranial Calcifications | Hearing Loss | Eye Impairment | Microcephaly | Bone Lesions | CNS Damage |
|---|---|---|---|---|---|---|
|
| + | - | + | + | - | + |
|
| - | - | - | + | + | + |
|
| + | + | + | + | + | + |
|
| - | - | - | - | + | + |
|
| - | - | + | - | - | + |
|
| + | + | + | + | - | + |
|
| - | + | + | + | + | + |
|
| + | + | + | + | - | + |
Figure 2Main forms of maternal–fetal transmission of cytomegalovirus (A). Main findings indicated by proteomic studies that explore the proteome of human cytomegalovirus (HCVM) infection (B).
Figure 3Main symptoms in children who contracted HIV through vertical transmission. Macrophages and microglia are reservoirs for viral multiplication and their immune functions are impaired (A). Main findings indicated by proteomic studies that explore the proteome of HIV infection (B).
Figure 4Congenital HSV infection can affect multiple organs, the central nervous system (CNS) and eyes, mouth and skin of newborns. Medical treatment is essential to avoid severe and irreversible damage (A). Main findings indicated by proteomic studies that explore the proteome of HSV infection (B).
Figure 5Malaria transmission cycle and representative proteomics-driven studies. (A) (1) Protozoa are transmitted to humans in the form of sporozoites through the bite of the female Anopheles mosquito. (2) Sporozoites reach the bloodstream and reach the liver, where they replicate in hepatocytes and mature in schizonts. Schizonts break and release merozoites. (3) Merozoites are capable of infecting erythrocytes, and initiate a cycle of asexual reproduction. Merozoites released in this step can restart a new cycle of asexual reproduction or they can start a cycle of sexual reproduction. (4) In sexual reproduction, male or female gametocytes are formed from merozoites. (5) Gametocytes can be absorbed by mosquitoes during the bite and start a cycle in the insect’s digestive tract. (6) Fertilization occurs that originates the oocyst, which migrates to the mosquito’s hemocele and releases sporozoites, which migrate to the mosquito’s salivary gland. Thus, when biting a new host, the cycle is restarted (1). (B) Main results of representative proteomic studies applied to malaria disease.
Figure 6Toxoplasmosis transmission cycle and representative proteomics-driven studies. (A) (1) In the cat, after ingesting tissues containing oocysts or cysts, these are released into the body and penetrate the intestinal epithelium where they undergo asexual reproduction followed by sexual reproduction, transforming into oocysts and can be excreted together with the feces. Oocysts can survive for months in the environment and are resistant to disinfectants, freezing, and drying, but destroyed by heating at 70 °C for 10 min. Other animals, such as pigs, sheep, rats, and including man (2) (intermediate hosts), can consume oocysts present in the environment and become contaminated. The oocyst ruptures in the intestine of the intermediate host, releasing the sporozoites that invade the enterocytes. In the enterocyte, each parasite is called a tachyzoite. Tachyzoites spread through the animal’s body and can form cysts in nervous and muscular tissue, which can be consumed by humans and cause infection (3). Tachyzoite multiplies asexually and disrupts the host cell. After the invasion of a new cell by a tachyzoite, the asexual cycle can lead to the formation of intracellular bradyzoites. The formation of bradyzoites begins to occur with greater intensity when the intermediate host develops specific immunity. (B) Main findings indicated by proteomic studies that explore the proteome of toxoplasmosis infection.
Figure 7In congenital syphilis, unlike infection in adults, Treponema pallidum is released into the fetus bloodstream and quickly reaches multiple organs. The main clinical symptom associated with disease in neonates is skin rashes, which spread throughout the body region. The main findings of the few studies that explore the proteome of syphilis infection are shown.
Representative proteomics-driven studies on TORCH associated infections. Examples on biological matrices analyzed, the proteomic strategy and the number of total protein identifications are reported.
| Disease | Matrix | MS Approach | Total Identifications | Reference |
|---|---|---|---|---|
|
| Human serum | Label-free quantification with SELDI-TOF-MS | Not available | [ |
| primary human fetal foreskin fibroblasts | TMT quantification and LC-MS/MS on Orbitrap Elite and Fusion | >8000 cellular proteins and 139 canonical and 14 ORFs viral proteins | [ | |
| ARPE-19 and Expi293F cells | Easy nLC 1000 HPLC system coupled to an Orbitrap Elite mass spectrometer | 1297 | [ | |
| Purified HCMV AD169 virions | Label-free quantification on a Finnigan LCQ ion trap MS | 59 | [ | |
| MRC5 human lung fibroblasts | Label-free quantification and TMT labeling on a LTQ-Orbitrap XL | 4000 host and 100 viral proteins | [ | |
| HFFs cells | SILAC labeling with 2D–LC-MS/MS (MudPIT) on a LCQ Deca XP Plus mass | 504 | [ | |
| HFFs cells | SILAC labeling with LC-MS/MS on a LTQ Orbitrap | 1719 | [ | |
| MRC5 cells | TMT labeling with nLC-MS/MS on a Q-Exactive HF | 5300 | [ | |
|
| HeLa and HFFs cells | iTRAQ labeling with LC–MS/MS on a TripleTOF 5600 | 3544 | [ |
| NPCs and iPSCs | TMT labeling with nLC-MS/MS on a Q-Exactive HF-Hybrid Quadrupole-Orbitrap | 6080 | [ | |
| Neurospheres | Label-free quantification on a 2D-RP/RP Synapt G2-Si mass spectrometer | Not available | [ | |
| NPCs and SK-N-BEB2 cell line | Label-free quantification with AP–LC–MS/MS on a LTQ-Orbitrap XL and Orbitrap Q Exactive HF | 386 ZIKV-interacting proteins and 1216 phosphorylation sites | [ | |
| Human serum | Label-free quantification with EASY-nLC 1000 on a Q Exactive High | 300 | [ | |
|
| Vaginal discharge | Label-free quantification with 2D-DIGE Nanoflow LC/MSMS on a QStar XL Qq-TOF | 72 protein spots with change in volume | [ |
| Monocytes and placental macrophages | Label-free quantification with SELDI-TOF and (LC MS/MS) | Not available | [ | |
| Placenta | Label-free quantification with LC–MS/MS on a LTQ XL | Not available | [ | |
|
| Purified virions | Label-free quantification with ESI-MS/MS on a QTRAP 4000 linear ion trap mass spectrometer | 37 | [ |
| HEp-2 cells line | Label-free quantification with 2-DE and LC-MS/MS on a Q-TOF 1 Mass Spectrometer | 103 protein spot changes | [ | |
| HEK293 cells | SILAC labeling with LC-MS/MS on a Q-Star Elite mass | At 4 hpi, 2178; At 24 hpi, 1947; At 10 hpi, 2099 | [ | |
| HFF cells | Label-free quantification with LC-MS/MS on a Orbitrap Fusion Tribrid mass spectrometer | 4000 | [ | |
| bEnd.3 cells | TMT labeling with nanoLC-MS/MS on a Q-Exactive Orbitrap | 6761 | [ | |
|
| Human blood | Label-free quantification with LC-MS/MS on a Linear Trap Quadrupole-Orbitrap Velos | 1527 | [ |
| Human plasma | Label-free quantification with 2D LC-MS on a LTQ ion trap | 1806 | [ | |
| Human plasma | Label-free quantification with Nano-LC–MS/MS on a LTQ-Orbitrap Velos | 504 | [ | |
| Human blood | Label-free quantification on a LTQ Orbitrap Velos | Not available | [ | |
| Infected placentas | TMT labeling with nano-LC-MS/MS on a Orbitrap Fusion | 2946 | [ | |
| Human erythrocytes cell culture | Label-free quantification on a micrOTOF-Q | 668 | [ | |
|
| Cysts from brain and muscle tissues of pigs | iTRAQ labeling with LC–MS/MS on a Q Exactive Orbitrap | 2551 | [ |
| Primary, neuronal and monocytic stem cells | iTRAQ labeling with LC/MS/MS on a LTQ Orbitrap Velos | 4367 | [ | |
| Brain mice | iTRAQ labeling with 2D-LC-MS/MS on a Orbitrap LC-MS | 2612 | [ | |
| Brain mice | Label-free quantification with LC-MS/MS on a Q-IT-OT Fusion Lumos | 1683 | [ | |
| Label-free quantification on a Q-Exactive Plus Orbitrap mass | 792 | [ | ||
| Mitochondria from parasites | Label-free quantification on a Q-Exactive Orbitrap | 400 | [ | |
|
| Urine | Label-free quantification on a 2D-LC-MALDI TOF/TOF and LC/ESI-IM-Q-TOF/HDMS | Not available | [ |
| DAL-1 strain bacteria isolated from rabbits | Label-free quantification on a MALDI-TOF/TOF and ESI-LTQ-Orbitrap | 557 | [ |